Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark GLP-1 Prior Auth Policy | OpenPayer
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 5694-D

    Prior Authorization Criteria for GLP-1 and GIP/GLP-1 Receptor Agonists

    Customize your policy alerts

    Sign up for cvs_caremark Policy 5694-D alerts

    Get alerted when Policy 5694-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prescription coverage and prior authorization for listed GLP-1 receptor agonists and tirzepatide, primarily for type 2 diabetes mellitus, including automated claim screening and clinical review when screening criteria are not met.

    Policy Summary
    PayerCVS Caremark
    PolicyPrior Authorization Criteria for GLP-1 and GIP/GLP-1 Receptor Agonists
    Policy CodePolicy 5694-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument one qualifying type 2 diabetes diagnostic criterion, including the required fasting duration when using fasting plasma glucose.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    7Products referenced
    36 monthsDuration of approval
    730 daysLookback period

    Coverage Criteria

    Type 2 Diabetes Mellitus

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Authorization may be granted when the patient has type 2 diabetes mellitus and ONE of the following criteria is met.

    Required diagnosis and qualifying evidence

    • The patient has a diagnosis of type 2 diabetes mellitus
    • ONE qualifying diagnostic criterion

      • A1C: The patient has a history of an A1C greater than or equal to 6.5 percent>= 6.5 percent

        Documentation is required for approval.

      • 2-hour plasma glucose during OGTT: The patient has a history of a 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during an oral glucose tolerance test (OGTT)>= 200 mg/dL

        Documentation is required for approval.

      • Random plasma glucose: The patient has a history of symptoms of hyperglycemia, such as polyuria, polydipsia, or polyphagia, or hyperglycemic crisis, and a random plasma glucose greater than or equal to 200 mg/dL>= 200 mg/dL

        Documentation is required for approval.

      • Fasting plasma glucose

        • The patient fasted for at least 8 hours prior to the fasting plasma glucose (FPG) measurementat least 8 hours

    Rybelsus is not indicated for patients with type 1 diabetes mellitus.

    Diagnostic and Automated Screening Rules

    A1C
    TestHemoglobin A1C
    Diagnostic thresholdAt least 6.5 percent
    Evidence requirementHistory of the qualifying A1C value; documentation is required for approval
    2-hour Plasma Glucose During OGTT
    TestTwo-hour plasma glucose during an oral glucose tolerance test (OGTT)
    Diagnostic thresholdAt least 200 mg/dL
    Evidence requirementHistory of the qualifying two-hour plasma glucose value; documentation is required for approval
    Random Plasma Glucose
    TestRandom plasma glucose
    Diagnostic thresholdAt least 200 mg/dL
    Required clinical contextSymptoms of hyperglycemia or hyperglycemic crisis; documentation is required for approval
    Fasting Plasma Glucose
    TestFasting plasma glucose (FPG)
    Diagnostic thresholdAt least 126 mg/dL
    Evidence requirementHistory of the qualifying FPG value; documentation is required for approval
    Fasting Duration
    Test conditionFasting before the qualifying fasting plasma glucose measurement
    Minimum fasting durationAt least 8 hours
    Documentation requirementDocumentation must establish the fasting duration before the FPG measurement
    Metformin Timing for Automated Screening
    MedicationMetformin
    Timing requirementThe metformin fill date must be at least 10 days before the claim for the requested drug
    Benefit requirementThe fill must occur under a prescription benefit administered by CVS Caremark
    Qualifying Antidiabetic-Drug History
    Medication historyAnother antidiabetic drug, excluding all target drugs
    Lookback periodWithin the past 730 days
    Benefit requirementThe fill must occur under a prescription benefit administered by CVS Caremark

    Prior Authorization and Documentation Requirements

    Prior Authorization

    Submit PA after a failed claim screen

    If the claim does not pass the initial screening logic, it will reject with a message indicating that prior authorization (PA) is required. Submit the request for evaluation by the PA unit, which will apply the clinical criteria.

    Prior Authorization

    Establish type 2 diabetes mellitus

    Authorization may be granted only when the patient has a diagnosis of type 2 diabetes mellitus and meets one of the specified diagnostic criteria.

    • A1C greater than or equal to 6.5 percent
    • 2-hour plasma glucose greater than or equal to 200 mg/dL during an OGTT
    • Symptoms of hyperglycemia or hyperglycemic crisis with random plasma glucose greater than or equal to 200 mg/dL
    • Fasting plasma glucose greater than or equal to 126 mg/dL after at least 8 hours of fasting
    Documentation Required

    Document qualifying diabetes evidence

    Documentation is required for approval when establishing type 2 diabetes mellitus through qualifying laboratory or symptomatic hyperglycemia evidence. Submit the relevant diagnostic history and results for the criterion being used.

    • A1C greater than or equal to 6.5 percent
    • 2-hour plasma glucose greater than or equal to 200 mg/dL during an OGTT
    • Symptoms of hyperglycemia or hyperglycemic crisis with random plasma glucose greater than or equal to 200 mg/dL
    • Fasting plasma glucose greater than or equal to 126 mg/dL
    Documentation Required

    Document at least 8 hours of fasting

    For the fasting plasma glucose criterion, documentation must establish that the patient fasted for at least 8 hours before the fasting plasma glucose measurement of at least 126 mg/dL.

    Denial Risk

    Avoid failure of automated diabetes screening

    A claim may reject and require prior authorization when it does not include an ICD-10 diagnosis code indicating type 2 diabetes mellitus and the patient has not met the automated screening history requirements. The screening may also require a qualifying diabetic-supply fill, metformin fill at least 10 days before the requested-drug claim, or another qualifying antidiabetic drug within the past 730 days.

    • Diabetic supply fill: at least a 30-day supply, excluding insulin pen needles and insulin syringes
    • Metformin: fill date at least 10 days before the requested-drug claim
    • Another antidiabetic drug: within the past 730 days, excluding all target drugs

    Policy Background

    This policy addresses injectable and oral GLP-1 receptor agonists and tirzepatide, a GIP/GLP-1 receptor agonist, used with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Certain products also include FDA-approved indications for cardiovascular or chronic kidney disease risk reduction.

    Diagnostic Definitions

    A1C Diagnostic Threshold
    DefinitionA1C diagnostic evidence
    Qualifying valueHemoglobin A1C value of at least 6.5 percent
    Approval requirementDocumentation is required for approval
    2-hour OGTT Diagnostic Threshold
    DefinitionTwo-hour OGTT diagnostic evidence
    Qualifying valueTwo-hour plasma glucose value of at least 200 mg/dL during an oral glucose tolerance test
    Approval requirementDocumentation is required for approval
    FPG Diagnostic Threshold
    DefinitionFasting plasma glucose diagnostic evidence
    Qualifying valueFasting plasma glucose value of at least 126 mg/dL
    Fasting conditionThe patient must fast for at least 8 hours before the test

    Initial Authorization for Type 2 Diabetes

    Initial Authorization for Type 2 Diabetes

    Authorization may be granted when the patient has type 2 diabetes mellitus and ONE diagnostic criterion is met.

    Required diagnosis and ONE qualifying diagnostic criterion

    • The patient has a diagnosis of type 2 diabetes mellitus
    • ONE qualifying diagnostic criterion

      • The patient has a history of an A1C greater than or equal to 6.5 percent>= 6.5 percent
      • The patient has a history of a 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during an oral glucose tolerance test (OGTT)>= 200 mg/dL
      • The patient has a history of symptoms of hyperglycemia, such as polyuria, polydipsia, or polyphagia, or hyperglycemic crisis, and a random plasma glucose greater than or equal to 200 mg/dL>= 200 mg/dL
      • The patient has a history of a fasting plasma glucose (FPG) greater than or equal to 126 mg/dL after fasting for at least 8 hours>= 126 mg/dL; fasting at least 8 hours
    Policy Summary
    PayerCVS Caremark
    PolicyPrior Authorization Criteria for GLP-1 and GIP/GLP-1 Receptor Agonists
    Policy CodePolicy 5694-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument one qualifying type 2 diabetes diagnostic criterion, including the required fasting duration when using fasting plasma glucose.
    SourceLink
    On This Page
    Coverage CriteriaDiagnostic and Automated Screening RulesPrior Authorization and Documentation RequirementsPolicy BackgroundDiagnostic DefinitionsInitial Authorization for Type 2 Diabetes